ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "SIGA Technologies, Inc." (SIGA) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"SIGA Technologies, Inc." (SIGA)

Rating: Sell Volatility: Conservative
Total Grade: D Industry: Biotechnology
Competitors: LJPC, ANAC, CBPO, RGEN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"SIGA Technologies, Inc."© quotemedia

Company Profile

SIGA Technologies, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical solutions for smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. Its lead product is ST-246, an orally administered antiviral drug that targets orthopoxviruses. The company also has two drug series in the pre-clinical development stage against four serotypes of virus for dengue disease. In addition, it is developing anti-arenavirus drug for hemorrhagic fever arenaviruses and other hemorrhagic fever viruses, including Rift Valley Fever, Lymphocytic choriomeningitis virus, and Ebola; and a broad spectrum antiviral candidate against viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. The company was founded in 1995 and is headquartered in New York, New York.

Recent News: "SIGA Technologies, Inc."